You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A Deep Learning Model to Quantify Arteriosclerosis in Donor Kidney Biopsies
SBC: NEWVENTUREIQ LLC Topic: 400ABSTRACT More people die every year from kidney disease than breast or prostate cancer. Kidney transplantation is life-saving, yet the donor organ shortage and high organ discard rate contributes to 13 deaths daily among patients awaiting transplant. The decision to use or discard a donor kidney relies heavily on microscopic quantitation of chronic damage by pathologists. The current standard of c ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Intraoperative Kit for AuNP-Tissue Grafts
SBC: G5 BIOLOGICAL INNOVATIONS LLC Topic: NIAMSProject Summary/Abstract The proposed technology is an intraoperative kit comprised of a liquid solution which will conjugate gold nanoparticles (AuNPs) to tissue grafts within minutes. Tissue grafts, such as those used in ACL reconstruction surgery, rarely achieve 100% graft assimilation, thereby leading to a host of problems. A potential solution is to modify the grafts in order to enhance integ ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
SBIR TOPIC 431- MOBILE ORAL-CANCER SCREENING AND TREATMENT (MOST) SYSTEM FOR LOW-RESOURCE SETTINGS
SBC: LIGHT RESEARCH INC. Topic: 431Oral and oropharyngeal squamous cell carcinoma (OSCC) together rank as the sixth most common cancer worldwide, it is the most common cancer in some low- and middle- income countries (LMICs). The poor survival rate in LMICs and rural regions in developed countries is mainly due to late diagnosis and the resultant progression of disease to an advanced stage at diagnosis. Motivated by the successes i ...
SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
TOPIC 434- ULTRA-FAST DOSE RATE (FLASH) RADIATION DETECTORS AND SAFETY SYSTEMS
SBC: TETRAIMAGING LLC Topic: 434Ultra-high dose rate radiotherapy or FLASH-RT, has shown the potential to drastically reduce the normal tissue toxicity without compromising tumor cell killing. Proton is the only treatment modality that can treat deep seated target in human body with FLASH-RT. With radiation dose delivered in less than a second, an ultra-fast quality assurance (QA) device is needed to verify the delivery of FLASH ...
SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
DEVELOPING A NOVEL NON-VIRAL NANOPIECES GENE DELIVERY SYSTEM FOR AD GENE THERAPY
SBC: Nanode Therapeutics, Inc. Topic: 4To develop a new, safe, and efficacious non-viral gene delivery system crossing the blood-brain barrier (BBB) for gene therapy of Alzheimer’s Disease (AD).
SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
High Endurance Attritable Hybrid Electric Drone
SBC: DRAGOON TECHNOLOGY LLC Topic: HR001121S000723An Inexpensive Long-Endurance Drone (ILED) requires a re-evaluation of the approach to UAS design and fielding. Future systems will be evaluated in terms of the capability of the swarm of aircraft instead of individual aircraft. This change in perspective will cause the design trades to look much different than those made in the initial development and evolution of today’s group 1 and group 2 ...
SBIR Phase I 2022 Department of DefenseDefense Advanced Research Projects Agency -
A digital intervention to decrease self-stigma among pregnant and postpartum women with opioid use disorder
SBC: Rissana, LLC Topic: NIDAProject Summary The opioid epidemic has resulted in widespread, detrimental public health consequences and disproportionally impacts vulnerable, high-risk groups including pregnant and postpartum women (PPW) and their babies. PPW with OUD also face high levels of self-stigma – the internalization of negative feelings about oneself because of drug misuse. Self-stigma is highly correlated with num ...
SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Lung Cancer, DNA Methylation, and Liquid Biopsy
SBC: DesertDx, LLC Topic: 102ABSTRACT Non-small cell lung cancer (NSCLC) remains a devastating disease with overall poor prognosis. Major contributing factors include obstacles to diagnosing the disease early in its course and limitations in currently available approaches to monitor therapeutic response. A liquid biopsy, or blood sample, can provide the epigenetic landscape of all cancerous lesions (primary and metastases). I ...
SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Development of novel ASO-based therapeutics for CMT1A
SBC: Shift Pharmaceuticals Holdings, Inc. Topic: 106Abstract: The objective of this project is to develop a safe, effective antisense oligonucleotide with Phosphorodiamidate Morpholino Oligomer (PMO) backbone chemistry capable of significantly reducing PMP22 protein production in Schwann cells, which is titratable in its dosing characteristics. For patients with CMT1A, the most common form of CMT, PMP22 over production of this protein drives diseas ...
SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Immunoplate-MALDI MS platform and assays
SBC: ISOFORMIX INC. Topic: 400PROJECT SUMMARY The goal of this proposal is to develop simple, robust and cost-effective Mass Spectrometry (MS)-based protein assays and platform by combining the best aspects of enzymatic immunoassays – plate based protein immunoaffinity capture, with the straightforward MS detection offered by MALDI-TOF MS. These immunoplate- MALDI MS assays are improved version of the enzymatic immunoassays ...
SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health